Not Signed In - Nuvelo Announces Completion Of Patient Enrollment In NAPA-2, First Phase 3 Trial Of Alfimeprase In Acute Peripheral Arterial Occlusion
Wed, 06 Sep 2006 07:00 AM EST
... Nuvelo, Inc. (Nasdaq: NUVO) today announced that it has completed patient enrollment in the first Phase 3 clinical trial of alfimeprase for the treatment of acute peripheral arterial occlusion (PAO), or "leg attack. [click link for full article] ...
Related Topics
- Clinical Trials
- Acute arterial occlusion - kidney
- Peripheral Neuropathy
- Patient Issues
- Blood Gases
- Peripheral arterial disease
- Peripheral Vascular Disease
- Personal Medical Records
- Coronary Occlusion
- Vascular Disease
- Acute Care
- Neuropathy
- Peripheral Blood Stem Cells
- Advocacy
- Peripheral Nerve Disorders
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Retinal artery occlusion
- Retinal vein occlusion
- Arterial embolism
email this page
print this page
bookmark this page
feedback on this page
